TWiV 1100: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles influenza and SARS-CoV-2, before discussing the development of new monoclonal antibody therapy, if vaccines and antivial drugs can used effectively together. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound including that after administration of the “oral remdesivir”, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if one can predict the loss infectivity of healthcare workers with mild COVID-19 disease and the dynamics of household transmission of the virus in children. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Measles tracking (CDC) Influenza/flu surveillance  (CDC) Influenza/flu map (CDC) COVID-19  hospital admissions (CDC) COVID-19 national trend (CDC) COVID-19 wastewater testing (biobot) Variant tracker (CDC) Variant hospital admissions (CDC) What new monoclonal antibody therapy? (FDA) A New pre-exposure prophylaxis for COVID-19? (Invivyd) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Really COVID-19 rebound after Nirmatrelvir-ritonavir treatment? (JAMA Network Open) Can vaccines and antiviral be effectiv...
Source: This Week in Virology - MP3 Edition - Category: Virology Authors: Source Type: podcasts